Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Wyeth-HMO-Formula

More Like This

PR Newswire associated0

Wyeth Becomes the First Multinational Company to Launch an HMO Growing-Up Infant Formula in China

PR Newswire associated0

New Illuma Growing-up Infant Formula Now Available throughout China

PR Newswire associated0

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

PR Newswire associated0

dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition

Access to Nutrition Initiative study reveals that Food for infants and toddlers from leading brands fails to meet marketing and nutritional standards

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

PR Newswire associated0

Yili Received Four World Dairy Innovation Awards at the 17th Global Dairy Congress

PR Newswire associated0

Yili's 2023 Revenue Reaches 126.2 Billion Yuan, Leading Global Dairy Industry towards Healthy and Sustainable Development